clinical trial · NCT04172441
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma·phase3·completed·n = 12
Congenital HyperinsulinismdasiglucagonPlacebo
brief summary
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.
started
Jun 19, 2020
primary completion
Feb 17, 2022
completion
Mar 7, 2022
last updated
Mar 14, 2025
official title
A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol